Molecular profiling of small bowel adenocarcinoma for personalized treatment
Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
This study is trying to find specific markers in small bowel adenocarcinoma to help create personalized treatment plans for patients with this rare cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Copenhagen University Hospital at Herlev Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 3 sites (Aarhus N and 2 other locations) |
| Trial ID | NCT06234306 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on small bowel adenocarcinoma, a rare cancer with limited understanding of its molecular characteristics and optimal management. The study aims to identify prognostic and predictive biomarkers through comprehensive molecular characterization, including DNA, RNA, and T-cell receptor sequencing. By developing consensus molecular subtypes, the research seeks to inform tailored treatment strategies, potentially improving patient outcomes. The findings could lay the groundwork for future clinical trials and personalized medicine approaches for this specific patient group.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with histologically verified small bowel adenocarcinoma.
Not a fit: Patients who do not have sufficient material for molecular testing or who have opted out of using their biological material for research may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment options for patients with small bowel adenocarcinoma.
How similar studies have performed: While small bowel adenocarcinoma is a rare condition, similar approaches in other cancers have shown promise in identifying molecular subtypes and improving treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years Exclusion criteria: Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\& Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.
Where this trial is running
Aarhus N and 2 other locations
- Department of Oncology, Aarhus University Hospital — Aarhus N, Denmark (Recruiting)
- Department Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet — Copenhagen Ø, Denmark (Recruiting)
- Department of Oncology Copenhagen University Hospital - Herlev and Gentofte — Herlev, Denmark (Recruiting)
Study contacts
- Principal investigator: Dan Høgdall, MD PhD — Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte
- Study coordinator: Dan Høgdall, MD PhD
- Email: danhog01@regionh.dk
- Phone: 004538681954
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.